莱索托家庭同日启动抗逆转录病毒治疗的两年随访:CASCADE试验
CASCADE试验比较家庭HIV检测时同日启动ART与常规照护,12个月时同日组关怀参与和病毒抑制更优;24个月时两组无显著差异,常规组12个月后补链接使差距缩小,未观察到同日组长期脱失或耐药突变补偿性增加。
要点
- 同日启动ART在12个月时改善关怀参与和病毒抑制。
- 24个月时两组关怀参与和病毒抑制无显著差异。
- 未发现同日启动ART导致长期脱失或耐药突变增加。
核心结论
- 同日启动ART在12个月时关怀参与和病毒抑制率更高,但24个月时与常规照护无显著差异。
- 差异消失源于常规照护组在12个月后补链接,未观察到同日组长期脱失补偿。
- 长期结果支持同日启动ART政策。
研究设计与样本
- CASCADE试验的两年随访分析,比较家庭HIV检测时同日启动ART与常规照护。
- 主要终点12个月完成后,追踪两组未在关怀中的参与者并鼓励就医。
- 24个月评估关怀参与、病毒抑制、未参与原因及同日组未链接者的耐药突变。
主要发现
- 36名24个月时存活且未在关怀中并确认状态者中,多数拒绝接触卫生系统或不愿服用ART。
- 8名受访同日组未链接者中,6人入组时未启动ART且未检测到获得性耐药突变;2人服用初始30天ART供应后获得耐药突变。
临床怎么用
- 同日启动ART可作为改善早期关怀参与和病毒抑制的策略。
- 需关注长期链接,常规照护组12个月后补链接可缩小差距。
- 对未链接者需了解拒绝接触卫生系统或不愿服药的原因。
局限性
- 24个月时部分参与者状态未确认,可能影响结果解释。
- 同日组未链接者访谈样本量小(8人),耐药突变分析受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The CASCADE trial showed that compared with usual care (UC), offering same-day (SD) antiretroviral therapy (ART) during home-based human immunodeficiency virus testing improved engagement in care and viral suppression 12 months after diagnosis. However, questions remain regarding long-term outcomes and the risk of propagating drug resistance. METHODS: After completion of the primary endpoint at 12 months, participants not in care in both arms were traced and encouraged to access care. At 24 months, the following outcomes were assessed in both arms: engagement in care, viral suppression, and reasons for nonengagement. Furthermore, we explored the acquisition of drug resistance mutations (DRMs) among SD arm nonlinkers. RESULTS: At 24 months, 64% (88/137) in the SD arm vs 59% (81/137) in the UC arm were in care (absolute difference [AD], 5%; 95% confidence interval [CI], -6 to16; P = .38) and 57% (78/137) vs 54% (74/137) had documented viral suppression (AD, 3%; 95% CI, -9 to 15; P = .28). Among 36 participants alive and not in care at 24 months with ascertained status, the majority rejected contact with the health system or were unwilling to take ART. Among 8 interviewed SD arm nonlinkers, 6 had not initiated ART upon enrollment, and no acquired DRMs were detected. Two had taken the initial 30-day ART supply and acquired DRMs. CONCLUSIONS: SD ART resulted in higher rates of engagement in care and viral suppression at 12 months but not at 24 months. Leveling off between both arms was driven by linkage beyond 12 months in the UC arm. We did not observe compensatory long-term disengagement in the SD arm. These long-term results endorse SD ART initiation policies. CLINICAL TRIALS REGISTRATION: NCT02692027.
引用
- Amstutz A, Brown JA, Ringera I, et al. Engagement in Care, Viral Suppression, Drug Resistance, and Reasons for Nonengagement After Home-Based Same-Day Antiretroviral Therapy Initiation in Lesotho: A Two-Year Follow-up of the CASCADE Trial. Clin Infect Dis. 2020. PMID: 31781759. doi:10.1093/cid/ciz1126
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。